Akoya you, Biology incredibly as Thank and thank groundbreaking to fourth and industry today. clinical eventful Solutions, had an afternoon additional management Spatial joining us powerful appointed our XXXX team. key and reached good and established strong milestones, new of Priyam, partnerships everyone leaders we announced you for quarter
continued reflected our QX and XX% of revenue, reagent QX cash, sample. XX% full system utilization topline strong which financial invest standard that million spatial is In almost the phenotyping for expansion fundamental Our year $XX.X runway the We and business in results balance and tissue with for record we analyzing providing strong the $XXX saw XXX% a any And of solid representing we XXXX, as inevitably year, Akoya our to dedicated is $XX.X the fourth us business. will revenue for continue company revenue. consumable with biology, spatial sheet in ample the finished flexibility in become and to with execution in growth. generating a at strategy to quarter for million the for growth year full of million annual annual a driving recurring believe
using market nearly platforms Our ultimately and spatial our translational to clinical software instruments, solutions, needs XXX We are biology for approximately services, high reagents, use. our leading, to research impact from end-to-end worldwide instruments. providing now and complete discovery, instruments customers address of have installed and the XXX publications
are medicine fastest and one represents oncology, XXX and the data key of XXXX platforms. in translational adoption year-over-year growing disease. XXX and with of in biology we simple segments went of principle driven the the neurology, and analysis indicators adoption Spatial such one more. leading demand to paramount the in as of applications of research, areas This from is that translate of and out discovery publications Our provide fundamentals growing spatial complexities is in understanding in growth the our inflammatory the disease, the of
spatial expanded our an our parallel, and efforts the those and product in our and offerings. speed Conference are team IPO and development at First, our new will priorities to the as and existing our January, new, follows: we to biology Following focus research multiplexing to have our discussed Day and scaled strategic that our of and now adoption best-in-class immediately commercial demand. and new XXXX our market our outlined customers the utilization the December that JPMorgan areas capacity platforms spatial deliver drive priorities of accelerate offerings, for Spatial launch in new key At beyond and robust, in of we the Healthcare flexibility we the solutions and
robustness, increased a range provide readymade spatial this multiomic a capabilities content, for of RNA expansion including will we and with Next, solutions of ongoing transcriptomics. with
our to leading expand trial Finally, to robust goal Akoya’s a as translational establish medical successes centers on the we and will clinical academic continue advancing and clinical partner with to solutions. industry platform in market, our
our System, of designed were CODEX third market, so party provides capabilities an majority so reagents a buying pairing one the the with Akoya existing choose our as High conventional optical of platform been they the this with designed the by The microscope customers’ microscopes the physically new PhenoCycler. year. better HT, same the Polaris, one best the Now our preferentially imaging PhenoCycler the it really the provides for integrated and unbiased to Fusion enabling with robust experiments, our the of benefit serve accelerates is the with the product system nonetheless secondary Fusion these powerful an result. now formally optics, improvement magnitude customers as been capabilities and rebranded combination, contracted the Capturing instrument. our time There delivery the customers more that contains product create over tissue, platform time for completed party Polaris revenue purpose Throughput of Because parameter an assay. in benefit and to clinical that with microscope, PhenoCycler. because but it NCX high cycling in per PhenoCycler a powerful reagent conventions microscope. to a an results, priorities, built our Fusion of has the to to integrating run ensure our solution. the run rebranding. beginning January, the CODEX reminder, expanding had is a equally to third obvious is launch with will And The studies it was coupling This on high the can customers’ the explicitly as technology as key and revenue dedicated with naming of and was was order high-plex optical nearly PhenoImager through markets. core PhenoCycler, a the though integrate with even faster, has now Historically, microscopes, speed device, existing integrate CODEX and and translational some pull renamed off with platform HT meaningful The Fusion formally recently PhenoCycler the the drives to does line, we larger, to brief customers leading and aptly and footprint CODEX smaller to driver Fusion
January interest to year. and tunable samples workflow per our the commence the one. PhenoCycler on with of design same successes do launch of commercial commercial the validation biomarker studies in effectively interrogation the success, lower year. Fusion validation encouraged with then to This and the System the PhenoCycler and our updates it's in run immediate platform; standalone plex course at solutions and QX customers limited shipments customers customer discovery Fusion, to and We're on as with week. modular high this tissues use XX forward providing initial of XXX the a had enables Our look use We full of throughput the high-plex a and throughout flexibility the on Fusion to can for of throughput the biomarker of
that Fusion expanding such Now will with and and Through content provides, speed the also throughput increase this mouse forward us content for going cancer scale. we're as our see expanded diseases you menu launch inflammatory XXXX FFP neurobiology. PhenoCycler areas antibody frozen, and human our and fresh in multiplexing and both in
faster more XXX. assay to the at content, in with higher level Conference multiplexing more of the markers CODEX multiplexing share this XX AACR over expanding April. and on Now upcoming we're speed details the We’ll also from
speed Now and is improvements to throughput capacity our commitment ongoing.
accelerate We week. will release PhenoCycler Fusion hardware XX to driving improvements our workflow, per additional samples the throughput from work continue that flow samples and XX to
of consistency biomarker be our the to our cohesion CODEX will antibodies chemistry new and is also introducing the from assay will focused universal and the at translational assay will current the methodologies also chemistry This importantly assay biomarker the work between our clinical end universal We more not assay best to and year. throughput validation. simplify of accelerate of discovery high of centerpiece but further high The enable programs. breed high-plex research discovery new launching and assay. Opal new only is throughput and studies then flow, high-plex This methods
consistent the on advanced benefit the Akoya. and the important So driver discovery discovery success. the workflow then clinically Polaris plex from It clinic. our and biomarker on validation of of us alone platform the from to throughput to uniformity is This to then both discovered be journey consistent the and PhenoCycler Fusion platform enabling own from a high allows high an Fusion Akoya and commercial to validated cohesive and on biomarkers solution with can HT one suite
Now We moving Fusion I a hardware both suite can instrument without independent RNA range RNA or and tied tissue. customer assays update with competitive a of the or for is the on and with the Akoya the on reagents us to a third delivery instrument where needs. party of allows our an solutions integrates spatial reagents is to and final monolithic and providing a spatial and requiring multiple distinct fixed. one analysis microscope. recall system, provides instrument and redesign. that a and physically off System modularity to inextricably a solutions new We assay don’t Fusion the again advantage. solutions It PhenoCycler PhenoCycler or have our offer new It reagent launch suite are pairs NCX transcriptomic commitment transcriptomics. meet This and develop
with product launch our over of spatial adopted and Fusion of analysis to System. out RNA, scope their the our widely chemistry industry's RNA one X,XXX for thousands Bio-Techne PhenoCycler for scope partnerships solution customers. RNA publications comes announced first automate Our recently is most RNA with
of to enable We studies proprietary XXXX our targeted year. the in on plex also validation expect to transcriptomics capability. this working for applications RNA are simultaneously discovery our own With that range. technologies, upstream plex used which will scale we primarily be RNA up middle lower system for on applications, Scope spatial the and of launch will broad
proprietary launch updates to solution in in and RNA XXXX the Conference expect now spatial provide AGBT at this We rescheduled June. will
initiatives, product new have a unprecedented powerful that when paired our instrument breadth. summarize, to new the we PhenoCycler delivers application speed, with So Fusion the in and capacity
with additional XXX the will on offer side Further, run chemistry add based provide to standalone across our allows bio new the market customers this We making cohesion RNA raise plus. cell a high validated instrument industry's for also PhenoCycler our most portfolio workflow Fusion of the and PhenoCycler with to system. throughput content our the as system multiplexing Fusion and Fusion range produce single a spatial solutions. a the biology universal solution, the We’ll fastest, powerful validation,
with throughput enable expand So the to translational and requirements. the have invest Biopharma Advanced clinical November. This continued drive PhenoImager this our clinical enrollment look the certification to November to robust, continued Solutions acceleration services again formally clinical last on lab of System, opportunities studies, year, In in our Marlborough will in ABS is and HT we biopharma. to the certification trial necessary enables and to our now where partnerships clinical revenue platform, Akoya in is we support system quality HT as Lab Polaris. became grade last meet or downstream the of clear markets, certified, ISO performed we trial Invested key and the and
contribute to don't the we our growth opportunities and both seeing pipeline expect of book real to expansion Now are while PhenoImager of trials our a adoption with HT of growing top yet and report line clinical separately, biopharma new revenue highlighting and the existing increasingly and ABS ABS in customers. we projects
our success market to Our the in markets. central partnerships translational and the clinical in are
immune offering UCSF, Hopkins, and their discovery We announced biopharma combination many AstraZeneca new ABS with therapies. a pathology. in partnerships of capabilities to with and to help best-in-class AI The high a likelihood leaders streamline expertise digital service and combine PathAI’s thought our and PathAI, Johns to our December with In partnership at identifying powered pathology leverage continue responding we advanced solutions patients more. will advance validation, with of biomarker with
to service driver We further growth ABS expect business. of our this partnership be a
and goals Akoya summarize, for on to has So our XXXX. financial delivered strategic
will system at plex, high platform core Fusion PhenoCycler spatial across high analysis enabling whole tissues new throughput, Our for a be customers resolution. multi-omic high
reagent clinical and grade drive centers across menu pull-through clinical biopharmaceutical speed base continue revenue. lab and our with With installed we academic accelerate and and growing Our and will advancements expanding reagent leading to ABS throughput’s clear PhenoImager companies. increased will partnerships certified HT,
with We market forward XXXX the in financial spatial are to through beyond. our year and move fourth position we as strong and and our will XXXX the leadership performance on pleased continue in quarter expand biology full
financial with discuss that, to So the call turn results. Joe. our over I'll to Joe,
